BRIEF published on 04/07/2026 at 07:05, 3 months 14 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 3 months 14 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 4 months ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 4 months ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 6 months 9 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 7 months 19 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 9 months 25 days ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 9 months 25 days ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 1 year 11 months ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 1 year 11 months ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 07/21/2026 at 17:05, 1 hour 20 minutes ago Caldwell Appoints Steven Price Co-Leader of Life Sciences & Healthcare Practice
Published on 07/21/2026 at 15:00, 3 hours 25 minutes ago Four Nines Gold Begins Maiden Drill Program at Hayden Hill
Published on 07/21/2026 at 15:00, 3 hours 25 minutes ago BlackBerry SecuSUITE Secures Renewed NIAP Common Criteria Certification, Reinforcing Leadership in Sovereign Government-Grade Secure Communications
Published on 07/21/2026 at 14:55, 3 hours 30 minutes ago Vulcan Minerals Inc. - Drilling Completed at Carbonear Zinc-Lead SEDEX Project in Newfoundland
Published on 07/21/2026 at 14:30, 3 hours 55 minutes ago Sarama Completes Sale of its West Australian Gold Assets
Published on 07/21/2026 at 18:15, 9 minutes ago EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
Published on 07/21/2026 at 17:50, 34 minutes ago The New Measure of an EV Isn't Range, It's Peace of Mind
Published on 07/21/2026 at 17:40, 45 minutes ago EQS-Adhoc: Airbus to present new mid-term outlook, strengthen commitment to profitable growth and shareholder returns during investor update
Published on 07/21/2026 at 17:37, 47 minutes ago EQS-Adhoc: Branicks Group AG updates the timetable for the publication of its 2025 annual and consolidated financial statements in light of ongoing restructuring negotiations
Published on 07/20/2026 at 18:20, 1 day ago Covivio - 2026 Half-year results: Earnings growth driven by active asset management
Published on 07/20/2026 at 18:04, 1 day ago Reporting on share buyback transactions carried out between July 8 and July 9, 2026
Published on 07/20/2026 at 17:40, 1 day ago Mersen selected to supply Ford and Leapmotor with fuses for electric vehicles
